

ESC Declaration of Interests Report

2024 ESC Guidelines for the management of peripheral arterial and aortic diseases

The ESC reviews relationships with healthcare industry and encourages transparency and ethical integrity.

It is mandatory for all experts involved in the development of ESC Guidelines to comply with the ESC Declaration and Management of Conflict of Interest Policy. Under this policy, they are required to submit a yearly Declaration of Interests (DOI) during the writing and reviewing phases of the Guidelines.

All DOIs presented in this report were assessed prior to work commencing and during the development of the Guidelines, according to the applicable review criteria in place at the time and as defined in the ESC Declaration and Management of Conflict of Interest Policy, Annex 3.

The most up-to-date version of the policy and its annexes are available on the ESC website at www.escardio.org/DOI.

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry | |
|-------------------------|------------------------------------|--|
| Boc Vinko | 2021 | Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Antithrombotic therapy |
| | 2022 | Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Peripheral Vascular and Cerebrovascular Disease |
| | 2023 | Nothing to be declared |
| Bossone Eduardo | 2021 | Nothing to be declared |
| | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Brodmann Marianne | 2021 | Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott Vascular, BD Bard, Biotronik, Medtronic, Philips, Cook Medical, Boston Scientific, Cagent, Reflow Medical : Vascular Medicine Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. European Expanded Panel |
| | 2022 | Nothing to be declared |
| | 2023 | Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Biotronik, Medtronic, Philips, Cordis, Cook, : Device Therapy |
| Bura Riviere Alessandra | 2021 | Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : anticoagulants Bayer Healthcare : anticoagulants |
| | 2022 | Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer Healthcare : Peripheral Vascular and Cerebrovascular Disease Pfizer : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry | |
|-------------------------|------------------------------------|--|
| Bura Riviere Alessandra | 2023 | <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. BMS : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Bayer : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure, Peripheral Vascular and Cerebrovascular Disease</p> |
| De Backer Julie | 2021 | <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. ESC Advocacy Committee</p> |
| | 2022 | <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of VASCERN (European Reference Network on Rare Multisystemic Vascular Disease) Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Member of Clingen Member of the Montalcino Aortic Consortium</p> |
| | 2023 | <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Baillet Latour Funds Funds for Scientific Research Flanders Special Research Fund Ghent University</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of VASCERN (European Reference Network on Rare Multisystemic Vascular Disease) Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Member of Clingen Member of the Montalcino Aortic Consortium Associate Editor for JACC</p> |
| Deglise Sebastien | 2021 | <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Cryolife : Aorta Medtronic : Aorta, Education Bayer AG : Peripheral arterial disease</p> |
| | 2022 | <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Research Methodology Artivion : Training and Education</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|------------------------|---|
| Deglise Sebastien | <p>2023 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Diseases of the Aorta Artivion : Diseases of the Aorta</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Abbott : Training and Education Boston Scientific : Training and Education</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Medtronic : Inclusion of patients in ernational registries dedicated to aortic diseases, site investigator Artivion : Inclusion of patients in ernational registries dedicated to aortic diseases, site investigator</p> |
| Della Corte Alessandro | <p>2021 Nothing to be declared</p> <p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Edwards Lifesciences : Valvular Heart Disease</p> <p>2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity MIUR (Italian Ministry for Research and Education)</p> |
| Heiss Christian | <p>2021 Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. European Society of Vascular Medicine German Society of Angiology Royal Society of Medicine German Society of Cardiology VascAgeNet UEMS Division of Vascular Medicine/Angiology Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Intramural funding University of Surrey UKRI Healthy Ageing Catalyst Award funding</p> <p>2022 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer Healthcare : Peripheral Vascular and Cerebrovascular Disease</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|---------------------------------|--|
| Heiss Christian | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity EPSRC Impact Acceleration Account EU Medical Research Council</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. European Society of Vascular Medicine, German Society of Vascular Medicine, British Cardiovascular Society, The Vascular Society for Great Britain and Ireland, German Society of Cardiology, Royal Society of Medicine, Royal College of Physicians, UEMS</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate Editor VASA</p> |
| Kaluzna-Oleksy Marta Izabela | <p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : heart failure Astra Zeneca : heart failure, diabetes mellitus Krka Pharma : hypertension, hyperlipidemia</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Polish Association of Heart Failure Patients</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Sanocor : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Polish Association for Heart Failure Patients</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry | |
|---------------------------------|------------------------------------|--|
| Kaluzna-Oleksy Marta Izabela | 2023 | <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Polish Medical Research Agency</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Acute Coronary Syndromes Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure</p> |
| Kurpas Donata | 2021 | Nothing to be declared |
| | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Lanzi Stefano | 2021 | Nothing to be declared |
| | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Mazzolai Lucia | 2021 | <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : anticoagulants Pfizer : Anticoagulants Daiichi Sankyo : lipid lowering Novartis : lipid lowering Sanofi Aventis : lipid lowering</p> |
| | 2022 | <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : Peripheral Vascular and Cerebrovascular Disease sigvaris : Peripheral Vascular and Cerebrovascular Disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Novartis : Set up of a clinical registry, coordinator</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|-----------------|---|
| Mazzolai Lucia | <p>2023 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Peripheral Vascular and Cerebrovascular Disease Otsuka Pharmaceuticals Development and Commercialization (consultancy) : Peripheral Vascular and Cerebrovascular Disease</p> |
| Mцениery Carmel | <p>2021 Receipt of royalties for intellectual property. Oxford University Press : Hypertension</p> |
| | <p>2022 Receipt of royalties for intellectual property. Oxford University Press : Hypertension</p> |
| | <p>2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Wellcome Receipt of royalties for intellectual property. Oxford University Press : Hypertension Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). President - ARTERY Society (Association for Research into Arterial Structure and Physiology)</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|-----------------|--|
| Mirault Tristan | <p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Incyte Biosciences : atherosclerosis, peripheral arterial disease, ponatinib Bayer Healthcare : peripheral arterial disease, rivaroxaban</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : atrial fibrillation, dabigatran Amgen : evolocumab</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Novartis : atherosclerosis, peripheral arterial disease, nilotinib Alexion : eculizumab Merck Sharp & Dohme : infliximab Novartis : iron overload deferoxamine Amgen : peripheral arterial disease, evolocumab Bayer Healthcare : peripheral arterial disease, rivaroxaban Bristol Myers Squibb : venous thromboembolism apixaban</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Genzyme : genetically modified iPS cells</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Société Française de Médecine Vasculaire: scientific committee Collège Français de Pathologie Vasculaire: Board Association Française des Syndrome d'Ehlers-Danlos: scientific committee Association Takayasu France: scientific committee</p> |
| | <p>2022</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Société Française de Médecine Vasculaire: scientific committee Collège Français de Pathologie Vasculaire: Board Association Française des Syndrome d'Ehlers-Danlos: scientific committee Association Takayasu France: scientific committee</p> |
| | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity APHP</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novo-Nordisk : Cardiovascular Disease in Special Populations Novartis : Risk Factors and Prevention Amarin : Risk Factors and Prevention</p> |
| | |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry | |
|-----------------|------------------------------------|---|
| Mirault Tristan | 2023 | <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Chair of the Scientific council of the French Society of Vascular Medicine Member of the French Society of Cardiology</p> |
| Pasquet Agnes A | 2021 | <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : general cardiology Servier : general cardiology Philips : imaging</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. member of the Belgian Society of Cardiology</p> |
| | 2022 | <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Philips : Echocardiography, Interventional Cardiology Daiichi Sankyo : Hypertension Servier : Other</p> |
| | 2023 | <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Philips : echography, contribution and support</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|--------------|---|
| Pitcher Alex | <p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Anticoagulation Bristol Myers Squibb : Anticoagulation Medtronic : Implantable Devices Novartis : Lipid Management (PCSK-9 inhibitors) Janssen-Cilag : Pulmonary Arterial Hypertension</p> <p>Receipt of royalties for intellectual property. Wiley Blackwell : General Medicine</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - ALL AREAS OF CARDIOLOGY - I am a director of Cardiologica Solutions limited, a small company which receives income from my private practice; income from consulting work for industry (declared above) and income from consulting work for the national health service in the UK of an educational nature. It is unlikely to supply or directly compete with the ESC, I include it here for complete transparency. Its annual turnover is less than about 20k Euros.</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring. I am directly employed in the UK Healthcare service, the National Healthcare service, (NHS), by Oxford University Hospitals NHS trust, and also offer private medical services in the UK.</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I hold a paid position with New College, Oxford University and at Oxford University I am a member of the British Medical Association I am a member of the British Cardiac Association I also receive occasional income (through the limited company listed above) for consulting activity in the NHS relating to the organisation of NHS services, and unrelated to ESC activities.</p> |
| | <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial Fibrillation (AF), Stroke Bristol Myers Squibb : Atrial Fibrillation (AF), Stroke Janssen-Cilag : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Novartis : Risk Factors and Prevention Medtronic : Syncope and Bradycardia</p> <p>Receipt of royalties for intellectual property. Wiley Blackwell : Clinical Skills</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|-----------------------------------|---|
| Pitcher Alex | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Janssen-Cilag : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Novartis : Risk Factors and Prevention</p> <p>Receipt of royalties for intellectual property. Wiley Blackwell : Clinical Skills</p> <p>Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - Diseases of the Aorta - A company which I control (Cardiologica Solutions Limited) holds a financial interest (is a partner in) a partnership in a healthcare company that delivers healthcare in the UK.</p> <p>Employment (including part time) in healthcare industry during the year for which you are declaring. Oxford University Hospitals NHS Foundation Trust : Consultant Cardiologist</p> |
| Rodriguez Palomares Jose Fernando | <p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Amyloidosis Takeda Pharmaceuticals : Fabry Amicus : Fabry disease</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. General Electric : Advanced cardiac imaging Circle Cardiovascular Imaging, Inc : Cardiovascular Magnetic resonance imaging</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Takeda Pharmaceuticals : Fabry Novartis : Heart failure</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amicus : Myocardial Disease</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. General Electric : Echocardiography</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|-----------------------------------|---|
| Rodriguez Palomares Jose Fernando | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Janssen-Cilag : Myocardial Disease Pfizer : Myocardial Disease</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Pfizer : Cardiac Magnetic Resonance (CMR)</p> |
| Schaubroeck Hannah | <p>2021</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abiomed : Impella Boehringer-Ingelheim : SGLT2-inhibitors - cardiorenal syndrome</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). GETINGE : Mechanical circulatory support (MCS)</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. board member of BIWAC</p> <hr/> <p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Acute Heart Failure Abiomed : Acute Heart Failure, Acute Cardiac Care, Other</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). GETINGE : MCS national registry (BIWAC), principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Board member (and past president) of Belgian Interdisciplinary working group of acute cardiology (BIWAC) - daughter organisation of BSC (Belgian society of Cardiology) BSC member (Belgian society of Cardiology) ISICEM faculty 2023 (International Symposium on Intensive Care and Emergency Medicine) ESICEM member (European society of Intensive Care Medicine)</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|--------------------|--|
| Schaubroeck Hannah | <p>2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Belgian Interdisciplinary Working group of Acute Cardiology (BIWAC) Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Acute Heart Failure Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Abiomed : Acute Heart Failure, Research Methodology Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. GETINGE : MCS national registry (BIWAC), principal investigator Membership or affiliation in political or advocacy groups working in the field of cardiology. Board member (and past president) of Belgian Interdisciplinary working group of acute cardiology (BIWAC) - daughter organisation of BSC (Belgian society of Cardiology) BSC member (Belgian society of Cardiology) ISICEM faculty 2023 (International Symposium on Intensive Care and Emergency Medicine) ESICEM member (European society of Intensive Care Medicine)</p> |
| Schlager Oliver | <p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bard : Drug eluting balloon Biotronik : PAD</p> <hr/> <p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biotronik : Peripheral Vascular and Cerebrovascular Disease</p> <hr/> <p>2023 Nothing to be declared</p> |
| Sirnes Per Anton | <p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : heart failure</p> <hr/> <p>2022 Nothing to be declared</p> <hr/> <p>2023 Nothing to be declared</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry | |
|---------------------|------------------------------------|---|
| Sprynger Muriel | 2021 | <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bristol Myers Squibb : anticoagulants (advisory services) Bayer : lower limb artery disease (podcast) Daiichi Sankyo : venous thromboembolic disease (advisory board)</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Scientific Committee of the Belgian Cardiology Liga (no payment)</p> |
| | 2022 | <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bristol Myers Squibb : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure</p> |
| | 2023 | Nothing to be declared |
| Stabile Eugenio | 2021 | Nothing to be declared |
| | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Steinbach Françoise | 2021 | <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Volunteer within the French Association Marfans and patient advocate within the European Reference network for rare vascular and multi systemic vascular diseases. Treasurer at the Marfan Europe Network</p> |
| | 2022 | <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Patient advocate at VASCERN, HTAD WG VP of French Marfan patient organisation Treasurer at Marfan Europe Network</p> |
| | 2023 | <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Patient advocate at VASCERN, HTAD WG VP of French Marfan patient organisation Treasurer at Marfan Europe Network</p> |
| Teixido Tura Gisela | 2021 | Nothing to be declared |
| | 2022 | <p>Travel and meeting support from healthcare industry, independent of the above activities. Johnson & Johnson : Other</p> |
| | 2023 | <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Novartis : Other Rovi : Other</p> |
| Thielmann Matthias | 2021 | Nothing to be declared |
| | 2022 | Nothing to be declared |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry | |
|----------------------|------------------------------------|---|
| Thielmann Matthias | 2023 | Nothing to be declared |
| van Kimmenade Roland | 2021 | <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : heart faillure Sanofi Aventis : heart failure Bayer Netherlands : heart failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Novartis : heart failure</p> |
| | 2022 | <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Chronic Heart Failure Bayer Netherlands : Chronic Heart Failure</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. VASCERN HTAD</p> |
| | 2023 | <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Dutch Heart Foundation</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Chronic Heart Failure Bayer Netherlands : Chronic Heart Failure</p> |
| Venermo Maarit | 2021 | <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Speaker fees</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Faron Pharmaceuticals : Info RAAA trial Bayer : Voyager trial</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - ALL AREAS OF CARDIOLOGY - Orion (ownership of shares)</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|----------------|---|
| Venermo Maarit | <p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Peripheral Vascular and Cerebrovascular Disease</p> |
| | <p>2023 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. WL Gore : Diseases of the Aorta</p> <p>Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Other - I am secretary general of the European Society for Vascular Surgery</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry | |
|------------------------------|------------------------------------|---|
| Arbelo Elena | 2022 | Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Atrial Fibrillation (AF) |
| | 2023 | Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Marató TV3 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Atrial Fibrillation (AF) Biosense Webster : Atrial Fibrillation (AF) |
| Begic Alden | 2022 | Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Myocardial Disease |
| | 2023 | Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Myocardial Disease |
| Behrendt Christian-Alexander | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Berukstis Andrius | 2022 | Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Device Therapy Travel and meeting support from healthcare industry, independent of the above activities. Medtronic : Training and Education |
| | 2023 | Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Terumo Inc : Clinical Skills Medtronic : Device Therapy |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|---------------|--|
| Boehm Michael | <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Chronic Heart Failure, Hypertension Amgen : Chronic Heart Failure, Hypertension Astra Zeneca : Chronic Heart Failure, Hypertension Bayer : Chronic Heart Failure, Hypertension Boehringer-Ingelheim : Chronic Heart Failure, Hypertension Medtronic : Chronic Heart Failure, Hypertension Novartis : Chronic Heart Failure, Hypertension Servier : Chronic Heart Failure, Hypertension Vifor International : Chronic Heart Failure, Hypertension Bristol Myers Squibb : Chronic Heart Failure, Hypertension Cytokinetics : Chronic Heart Failure, Hypertension</p> <hr style="border-top: 1px dashed black;"/> <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott : Chronic Heart Failure, Hypertension Amgen : Chronic Heart Failure, Hypertension Astra Zeneca : Chronic Heart Failure, Hypertension Bayer : Chronic Heart Failure, Hypertension Boehringer-Ingelheim : Chronic Heart Failure, Hypertension Medtronic : Chronic Heart Failure, Hypertension Novartis : Chronic Heart Failure, Hypertension Servier : Chronic Heart Failure, Hypertension Vifor International : Chronic Heart Failure, Hypertension Bristol Myers Squibb : Chronic Heart Failure, Hypertension Cytokinetics : Chronic Heart Failure, Hypertension</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|----------------|---|
| Bondue Antoine | <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Atrial Fibrillation (AF), Stroke Pfizer : Myocardial Disease Takeda Pharmaceuticals : Myocardial Disease Bristol Myers Squibb : Myocardial Disease Alynlam : Myocardial Disease MyoKardia : Myocardial Disease Amicus : Myocardial Disease</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bristol Myers Squibb : Myocardial Disease Alynlam : Myocardial Disease MyoKardia : Myocardial Disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Johnson & Johnson : Chair on Pulmonary Hypertension, Supervisor, investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. President of the Scientific committee of the Belgian Heart Ligue</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|------------------|---|
| Bondue Antoine | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Atrial Fibrillation (AF), Stroke Pfizer : Myocardial Disease Takeda Pharmaceuticals : Myocardial Disease Bristol Myers Squibb : Myocardial Disease Alnylam : Myocardial Disease MyoKardia : Myocardial Disease Amicus : Myocardial Disease</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bristol Myers Squibb : Myocardial Disease Alnylam : Myocardial Disease MyoKardia : Myocardial Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Johnson & Johnson : Chair on Pulmonary Hypertension, Supervisor, investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. President of the Scientific committee of the Belgian Heart Ligue</p> |
| Borger Michael A | <p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Artivion (formerly CryoLife) : Diseases of the Aorta Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|--------------------------|--|
| Borger Michael A | <p>2023 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Artivion (formerly CryoLife) : Diseases of the Aorta Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease</p> |
| Bosevski Marijan | <p>2022 Nothing to be declared</p> <hr/> <p>2023 Nothing to be declared</p> |
| Bouزيد Mohammed El Amine | <p>2022 Nothing to be declared</p> <hr/> <p>2023 Nothing to be declared</p> |
| Brida Margarita | <p>2022 Nothing to be declared</p> <hr/> <p>2023 Nothing to be declared</p> |
| Buccheri Sergio | <p>2022 Nothing to be declared</p> <hr/> <p>2023 Nothing to be declared</p> |
| Buchanan Gill Louise | <p>2022 Membership or affiliation in political or advocacy groups working in the field of cardiology. British Cardiovascular Society - Non Surgical Centre Council Representative</p> <hr/> <p>2023 Membership or affiliation in political or advocacy groups working in the field of cardiology. British Cardiovascular Society - Women Committee Member British Cardiovascular Intervention Society</p> |
| Caruana Maryanne | <p>2022 Nothing to be declared</p> <hr/> <p>2023 Membership or affiliation in political or advocacy groups working in the field of cardiology. Chairperson, Beating Hearts Malta - voluntary organisation for children and adults with congenital heart disease in Malta Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate Editor, General Cardiovascular Medicine for Frontiers in Cardiovascular Medicine since September 2023</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|------------------------|--|
| Chioncel Ovidiu | <p>2022 Travel and meeting support from healthcare industry, independent of the above activities. Servier : Chronic Heart Failure</p> |
| | <p>2023 Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Servier ESC 2023 Congress attendance support : Chronic Heart Failure</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate Editor: BMC Cardiovascular Disorders Exploration in Medicine Cardiac Failure Review Journal of Acute Disease</p> |
| Christersson Christina | <p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bristol Myers Squibb : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Bayer : Valvular Heart Disease</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial Fibrillation (AF), Valvular Heart Disease</p> |
| | <p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Bristol Myers Squibb : Chronic Heart Failure Pfizer : Valvular Heart Disease</p> |
| De Borst Gert J | <p>2022 Research funding from healthcare industry under your direct/personal responsibility (to department or institution). International Cardio Corporation : Unrestricted grant: development of high frequency ultrasound application for treatment of atherosclerotic disease, chief investigator</p> |
| | <p>2023 Nothing to be declared</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|---------------------|---|
| De Carlo Marco | <p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Sanofi Aventis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Medtronic : Interventional Cardiology</p> |
| | <p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Sanofi Aventis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Medtronic : Interventional Cardiology</p> |
| Delle-Karth Georg | <p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer Healthcare : Chronic Heart Failure Abbott : Clinical Skills Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Travel and meeting support from healthcare industry, independent of the above activities. Boehringer-Ingelheim : Clinical Skills</p> |
| | <p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer Healthcare : Chronic Heart Failure Abbott : Clinical Skills Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Edwards Lifesciences : Training and Education, Valvular Heart Disease</p> |
| Georgiou Georgios P | <p>2022 Nothing to be declared</p> |
| | <p>2023 Nothing to be declared</p> |
| Gimelli Alessia | <p>2022 Travel and meeting support from healthcare industry, independent of the above activities. GE Healthcare : Nuclear Imaging</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry | |
|-----------------------|------------------------------------|---|
| Gimelli Alessia | 2023 | Nothing to be declared |
| Gonzalez Gomez Ariana | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Gottardi Roman | 2022 | <p>Direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Supplier - Shareholder of TEVAR Ltd (South Africa) a start-up company developing a non-occlusive Stent-Graft molding balloon catheter. Shareholder of Ascense Medical GmbH (Austria) a start-up company developing compliant vascular and endovascular protheses to maintain the windkessel effect of the aorta both companies are in the development phase and have currently no medical device on the market</p> |
| | 2023 | <p>Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Supplier - Shareholder of TEVAR Ltd (South Africa) a start-up company developing a non-occlusive Stent-Graft molding balloon catheter. Shareholder of Ascense Medical GmbH (Austria) a start-up company developing compliant vascular and endovascular protheses to maintain the windkessel effect of the aorta both companies are in the development phase and have currently no medical device on the market</p> |
| Hanna Lydia | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Hinterbuchner Lynne | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Ibanez Borja | 2022 | <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomía, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|---------------------|---|
| Ibanez Borja | <p>2023 Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomía, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p> |
| Ibrahimi Pranvera | <p>2022 Nothing to be declared</p> <p>2023 Nothing to be declared</p> |
| Ikonomidis Ignatios | <p>2022 Nothing to be declared</p> <p>2023 Nothing to be declared</p> |
| Indolfi Ciro | <p>2022 Nothing to be declared</p> <p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Chiesi Pharma : Acute Coronary Syndromes</p> |
| James Stefan | <p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Prinicpal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|-------------------|---|
| James Stefan | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Wallenberg foundation, Swedish heart and lung foundation</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Elixir : clinical trial, study chair MSD : Clinical trial, trial executive committee Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p> |
| Jondeau Guillaume | <p>2022 Nothing to be declared</p> <hr/> <p>2023 Nothing to be declared</p> |
| Jug Borut | <p>2022 Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. As member of the national committee for medicines reimbursement, I cannot enter in any direct or indirect relationship with industry sponsors.</p> <hr/> <p>2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Slovenian Research Agency</p> |
| Kahan Thomas | <p>2022 Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Medtronic : Reimbursement to institution for participation in clinical research (trial registry), Site investigator Recor : Reimbursement to institution for participation in clinical research, Site investigator</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|------------------|--|
| Kahan Thomas | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Medtronic : Reimbursement to institution for participation in clinical research (trial registry), Site investigator Recor : Reimbursement to institution for participation in clinical research, Site investigator</p> |
| Kallenbach Klaus | <p>2022</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Edwards Lifesciences : Cardiovascular Surgery</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. EACTS, DGTHG</p> <hr/> <p>2023</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. EACTS, DGTHG</p> |
| Kober Lars | <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure</p> <hr/> <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Novo-Nordisk : Chronic Heart Failure</p> |

2024 ESC Guidelines for the management of peripheral arterial and aortic diseases - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|-----------------------|---|
| Kolossvary Endre | <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. AbbVie : Other Egis Pharma : Peripheral Vascular and Cerebrovascular Disease Richter : Peripheral Vascular and Cerebrovascular Disease Pfizer : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Egis Pharma : European Society of Cardiology</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Presidency of the Hungarian Society of Angiology and Vascular Surgery Board Membership in the Hungarian Society of Hypertension National delegate in the Society of International Angiology Membership in the Advisory Board of VAS (European Independent Foundation in Angiology/ Vascular Medicine)</p> |
| | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Egis Pharma : Peripheral Vascular and Cerebrovascular Disease</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I am the president of the Hungarian Society of Angiology and Vascular Surgery.</p> |
| Koskinas Konstantinos | <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry | |
|-----------------------|------------------------------------|---|
| Koskinas Konstantinos | 2023 | <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> |
| Koslowsky Jonathan | 2022 | <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Pharmacology and Pharmacotherapy Novartis : Pharmacology and Pharmacotherapy</p> |
| | 2023 | <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Pharmacology and Pharmacotherapy Novartis : Pharmacology and Pharmacotherapy</p> |
| Kospanov Nursultan | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Laxdal Elin H | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Lottermoser Katja | 2022 | <p>Travel and meeting support from healthcare industry, independent of the above activities. Daichi-Sanyo : Risk Factors and Prevention</p> |
| | 2023 | Nothing to be declared |
| Lunegova Olga | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|---------------------|---|
| Madaric Juraj | <p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Peripheral Vascular and Cerebrovascular Disease Pfizer : Peripheral Vascular and Cerebrovascular Disease Medtronic : Peripheral Vascular and Cerebrovascular Disease, Interventional Cardiology</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Pfizer : clinical research grant - deep venous thrombosis, principal investigator</p> |
| | <p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Peripheral Vascular and Cerebrovascular Disease Pfizer : Peripheral Vascular and Cerebrovascular Disease Zentiva : Peripheral Vascular and Cerebrovascular Disease, Hypertension Medtronic : Peripheral Vascular and Cerebrovascular Disease, Interventional Cardiology</p> |
| Maurel Blandine | <p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Philips : Cardiovascular Surgery Cook Medical : Cardiovascular Surgery Gore : Cardiovascular Surgery</p> |
| | <p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Cook Medical : Diseases of the Aorta Gore : Diseases of the Aorta</p> |
| Mcevoy John William | <p>2022 Nothing to be declared</p> |
| | <p>2023 Nothing to be declared</p> |
| Meltzer Gil | <p>2022 Nothing to be declared</p> |
| | <p>2023 Nothing to be declared</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|---------------------|--|
| Mihaylova Borislava | <p>2022 Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Merck Sharp & Dohme : economic analyses alongside a clinical trial, senior health economist Barts Charity : Research project, principal investigator National Institute for Health Research (UK), Health Technology Assessment Programme : Research project, principal investigator Bowel Research UK : research project, principal investigator</p> <hr/> <p>2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Barts Charity, UK Bowel Research UK Cancer Research UK National Institute for Health and Care Research, UK</p> |
| Mindham Richard | <p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. PASSpaces. http://passpaces.co.uk/. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. I support the British charity CardiomyopathyUK, https://www.cardiomyopathy.org.uk/. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, https://pumpingmarvellous.org/. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, https://bureaucracyincts.eu/. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not control the purchase & sale of shares and I do not know whether any shares are in medical companies.</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|----------------------|--|
| Mindham Richard | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. NiCE (National Institute for Health & Care Excellence) - UK Government body. Guideline development.. Commences January 2024. : Chronic Heart Failure</p> <p>PASSpaces. http://passpaces.co.uk/. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. I support the British charity CardiomyopathyUK, https://www.cardiomyopathy.org.uk/. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, https://pumpingmarvellous.org/. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, https://bureaucracyincts.eu/. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not not control the purchase & sale of shares and I do not know whether any shares are in medical companies.</p> |
| Monaghan Monica | <p>2022 Nothing to be declared</p> <hr/> <p>2023 Nothing to be declared</p> |
| Mozos Ioana Monica | <p>2022 Nothing to be declared</p> <hr/> <p>2023 Nothing to be declared</p> |
| Nielsen Jens Cosedis | <p>2022 Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Have received research funding to my institution for independent research from the Danish Heart Foundation and the Novo Nordisk Foundation.</p> <hr/> <p>2023 Nothing to be declared</p> |
| Pavesi Pier Camillo | <p>2022 Nothing to be declared</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry | |
|---------------------|------------------------------------|--|
| Pavesi Pier Camillo | 2023 | Nothing to be declared |
| Petrov Ivo | 2022 | <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Device Therapy, Valvular Heart Disease, Diseases of the Aorta</p> <p>Research funding (personal) from healthcare industry. Contego : PERFORMANCE ONE, Performance II top recruiter, Principal Investigator</p> |
| | 2023 | <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : 2 items checked</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Valvular Heart Disease</p> |
| Prescott Eva | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Prochazka Pavel | 2022 | <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Cordis : Other</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Medtronic Foundation : Diseases of the Aorta, Peripheral Vascular and Cerebrovascular Disease, Stroke, Other</p> |
| | 2023 | <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Cordis : Other</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Abbott Vascular : Diseases of the Aorta, Peripheral Vascular and Cerebrovascular Disease Medtronic Foundation : Diseases of the Aorta, Peripheral Vascular and Cerebrovascular Disease, Stroke, Other</p> |
| RAISSUNI Zainab | 2022 | Nothing to be declared |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|-------------------------|--|
| RAISSUNI Zainab | <p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis servier pfizer : Chronic Heart Failure</p> |
| Rakisheva Amina | <p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure</p> |
| | <p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure</p> |
| Rantner Barbara | <p>2022 Nothing to be declared</p> |
| | <p>2023 Nothing to be declared</p> |
| Rasiova Maria | <p>2022 Nothing to be declared</p> |
| | <p>2023 Nothing to be declared</p> |
| Rasmussen Torsten Bloch | <p>2022 Travel and meeting support from healthcare industry, independent of the above activities. Novo-Nordisk : Cardiovascular Disease in Special Populations</p> <p>Direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - Cardiovascular Disease in Special Populations - I am a shareholder in Novo-Nordisk. The value of the shares is approximately 7600 Euros.</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry | |
|-------------------------|------------------------------------|---|
| Rasmussen Torsten Bloch | 2023 | <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Myocardial Disease Sanofi Aventis : Myocardial Disease Bristol Myers Squibb : Myocardial Disease</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Novo-Nordisk : European Society of Cardiology</p> <p>Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - Cardiovascular Disease in Special Populations - I am a shareholder in Novo-Nordisk. The value of the shares is approximately 7600 Euros.</p> |
| Ricco Jean-Baptiste | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Righini Marc | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Rocca Bianca | 2022 | <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Aboca SRL : Other</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer AG : study on low dose rivaroxaban, Chief investigator</p> |
| | 2023 | <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Cancer UK</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Aboca, SRL : Other</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry | |
|---------------------------|------------------------------------|---|
| Rocca Bianca | 2023 | <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editorial Board of: Assistant Editor Diabetes and Vascular Disease Research Advisory Board: Pharmadvances. Associate Editor: Cardiovascular Drugs and Therapy, Clinical Pharmacology Editorial Board: Bleeding, Thrombosis, and Vascular Biology Associate Editor. Frontiers in Drug Safety and Regulation Section on Cardiovascular Drug Safety Associate Editor for European Cardiology Review Editorial Board European Journal of Preventive Cardiology Editorial Board Journal of Thrombosis and Thrombolysis Editorial Board International Journal of Cardiology</p> |
| Rossello Francisco Javier | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Rudzitis Ainars | 2022 | <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Atrial Fibrillation (AF) Boehringer-Ingelheim : Chronic Heart Failure</p> |
| | 2023 | <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Pfizer : Myocardial Disease</p> |
| Saari Petri | 2022 | <p>Travel and meeting support from healthcare industry, independent of the above activities. Boston Scientific : Peripheral Vascular and Cerebrovascular Disease Medtronic : Peripheral Vascular and Cerebrovascular Disease B.Braun : Peripheral Vascular and Cerebrovascular Disease BD : Peripheral Vascular and Cerebrovascular Disease Stryker : Stroke</p> |
| | 2023 | <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Cook Medical : Diseases of the Aorta Stryker : Peripheral Vascular and Cerebrovascular Disease</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry | |
|--------------------|------------------------------------|--|
| Sadek Yasser | 2022 | Nothing to be declared |
| | 2023 | Membership or affiliation in political or advocacy groups working in the field of cardiology. Secretary of the Egyptian society of cardiology |
| Samadov Fuad | 2022 | Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Servier : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Novartis : Risk Factors and Prevention |
| | 2023 | Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Novartis : Risk Factors and Prevention |
| Samstad Stein Olav | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Schmid Jean-Paul | 2022 | Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Bayer AG : Risk Factors and Prevention Boehringer-Ingelheim : Risk Factors and Prevention, Rehabilitation and Sports Cardiology |
| | 2023 | Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Risk Factors and Prevention |
| Sokolov Maksym | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|-----------------------|--|
| Stamatelopoulos Kimon | <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Chronic Heart Failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Amgen : Grant support for investigator initiated study regarding the effect of carfilzomib on cardiovascular function in patients with multiple myeloma, co-Principal Investigator</p> |
| | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Chronic Heart Failure</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Amgen : Grant support for investigator initiated study regarding the effect of carfilzomib on cardiovascular function in patients with multiple myeloma, co-Principal Investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Received a non-research grant titled: "Raising awareness and promoting timely diagnosis for TTR Amyloidosis through Digital Health" ID: 76080197, under Healthcare Alliance for Amyloidosis (Globalbridges.org), Mayo Clinic, US & funded by Pfizer (130k USD). Granted to the Department of Clinical Therapeutics, National and Kapodistrian University of Athens. PI: Kimon Stamatelopoulos. Aim: to increase awareness of TTR amyloidosis in Greece. Time frame 2023-2025.</p> |
| Staub Daniel | <p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Philips : Cross-Modality and Multi-Modality Imaging Topics Bracco Pharmaceutical : Cross-Modality and Multi-Modality Imaging Topics Bauerfind : Other Daiichi Sankyo : Pharmacology and Pharmacotherapy Bristol Myers Squibb : Pharmacology and Pharmacotherapy Bayer AG : Pharmacology and Pharmacotherapy Sanofi Aventis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Philips : Ultrasound research in new ultrasound technology by supporting with new technologies , chief investigator</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|-----------------|---|
| Staub Daniel | <p>2023</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Philips : Peripheral Vascular and Cerebrovascular Disease Sanofi Aventis : Risk Factors and Prevention, Pharmacology and Pharmacotherapy</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Bayer : XATOC: Xarelto vascular in PAD patients register study, site investigator</p> |
| Steiner Sabine | <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : Peripheral Vascular and Cerebrovascular Disease Cook Medical : Peripheral Vascular and Cerebrovascular Disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bard : Research agreement, Principal investigator</p> <hr/> <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity German Research Foundation</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Peripheral Vascular and Cerebrovascular Disease Cook Medical : Peripheral Vascular and Cerebrovascular Disease iThera Medical : Peripheral Vascular and Cerebrovascular Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Bard : Research agreement, Principal investigator</p> |
| Sudano Isabella | <p>2022</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Amgen Inc : Risk Factors and Prevention</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swiss Society of hypertension, Swiss heart Foundation, Swiss Atherosclerosis society, Forum for Tobacco prevention in hospital setting Board Member, all voluntary participation</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|-----------------|---|
| Sudano Isabella | <p>2023</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Recor Medical : Risk Factors and Prevention</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swiss Society of hypertension, Swiss heart Foundation, Swiss Atherosclerosis society, Forum for Tobacco prevention in hospital setting Board Member, all voluntary participation</p> |
| Tarmiz Amine | <p>2022 Nothing to be declared</p> <p>2023 Nothing to be declared</p> |
| Teraa Martin | <p>2022</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Terumo Inc : Diseases of the Aorta</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Editorial Board Member of European Journal of Vascular and Endovascular Surgery, European Journal of Vascular and Endovascular Surgery Vascular Forum, and Annals of Vascular Surgery. Regular Faculty Member at European Society for Vascular Surgery (ESVS) Annual Meetings. Board Member of the European Vascular Research Collaborative (EVRC).</p> <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity ZonMw</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Terumo Aortic : Diseases of the Aorta</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Terumo Inc : Diseases of the Aorta</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry | |
|-------------------------|------------------------------------|--|
| Teraa Martin | 2023 | Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editorial Board Member of European Journal of Vascular and Endovascular Surgery, European Journal of Vascular and Endovascular Surgery Vascular Forum, and Annals of Vascular Surgery. Regular Faculty Member at European Society for Vascular Surgery (ESVS) Annual Meetings. Board Member of the European Vascular Research Collaborative (EVRC). |
| Tiefenbacher Christiane | 2022 | Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Bayer Healthcare : Chronic Heart Failure Daijchi : Chronic Heart Failure |
| | 2023 | Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Bayer Healthcare : Chronic Heart Failure Daijchi : Chronic Heart Failure |
| Timoteo Ana Teresa | 2022 | Travel and meeting support from healthcare industry, independent of the above activities. Astra Zeneca : Chronic Heart Failure Servier : Chronic Heart Failure |
| | 2023 | Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associated Editor in Frontiers in Cardiovascular Imaging. |
| Truusalu Jaagup | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Tsaturyan Arsen | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Tutar Eralp | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry | |
|---------------------------|------------------------------------|--|
| Vaartjes Ilonca | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Vidal-Perez Rafael Carlos | 2022 | <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Chronic Heart Failure Amgen : Risk Factors and Prevention Servier : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention Organon : Risk Factors and Prevention</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Daiichi Sankyo : Atrial Fibrillation (AF) Rovi : Chronic Heart Failure</p> |
| | 2023 | <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo : Atrial Fibrillation (AF) Almirall Spain : Risk Factors and Prevention Organon : Risk Factors and Prevention</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Bayer : Atrial Fibrillation (AF) Daiichi Sankyo : Atrial Fibrillation (AF) Rovi : Chronic Heart Failure Novo-Nordisk : Risk Factors and Prevention</p> |
| Vrints Christiaan J M | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|-----------------------|---|
| Vrkic Kirhmajer Majda | <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Eli Lilly : Cardiovascular Disease in Special Populations Novo-Nordisk : Cardiovascular Disease in Special Populations Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Peripheral Vascular and Cerebrovascular Disease, Risk Factors and Prevention Pfizer : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Bayer : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure, Peripheral Vascular and Cerebrovascular Disease</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Pfizer : European Society of Cardiology</p> <hr style="border-top: 1px dashed black;"/> <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Eli Lilly : Cardiovascular Disease in Special Populations Novo-Nordisk : Cardiovascular Disease in Special Populations Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Peripheral Vascular and Cerebrovascular Disease, Risk Factors and Prevention Pfizer : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Bayer : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure, Peripheral Vascular and Cerebrovascular Disease</p> |
| Zeppenfeld Katja | <p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Biosense Webster : investigator initiated research, PI</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|------------------|--|
| Zeppenfeld Katja | <p>2023</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biosense Webster : Investigator initiated research, ventricular arrhythmias, PI</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|------------------|---|
| Arbelo Elena | <p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Atrial fibrillation</p> |
| | <p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Atrial Fibrillation (AF)</p> |
| | <p>2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Marató TV3</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Atrial Fibrillation (AF) Biosense Webster : Atrial Fibrillation (AF)</p> |
| Baigent Colin | <p>2021 Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boehringer-Ingelheim : Renal disease</p> |
| | <p>2022 Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boehringer Ingelheim : Grant to the University of Oxford for the EMPA-KIDNEY trial, Co-PI</p> |
| | <p>2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity UK Medical Research Council</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Boehringer-Ingelheim : Funding provided for the coordination of the EMPA-KIDNEY trial, Chair of Steering Committee</p> |
| Borger Michael A | <p>2021 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Cryolife : aortic surgery Abbott : heart valve therapy Edwards Lifesciences : heart valve therapy Medtronic : heart valve therapy</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|------------------|---|
| Borger Michael A | <p>2022 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Artivion (formerly CryoLife) : Diseases of the Aorta Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease</p> |
| | <p>2023 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Artivion (formerly CryoLife) : Diseases of the Aorta Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease</p> |
| Buccheri Sergio | <p>2021 Nothing to be declared</p> |
| | <p>2022 Nothing to be declared</p> |
| | <p>2023 Nothing to be declared</p> |
| Ibanez Borja | <p>2021 Nothing to be declared</p> |
| | <p>2022 Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p> |
| | <p>2023 Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|--------------|--|
| James Stefan | <p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Proctorship</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Clinical trial executive committee Bayer : Clinical trial executive committee Elixir : Clinical trial executive committee jansen : Clinical trial executive committee Amgen : Clinical trial steering committee Novo-Nordisk : Clinical trial steering committee</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Astra Zeneca : Clinical trial Amgen : Clinical trial leadership Elixir : Clinical trial leadership</p> |
| | <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|--------------|---|
| James Stefan | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Wallenberg foundation, Swedish heart and lung foundation</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Elixir : clinical trial, study chair MSD : Clinical trial, trial executive committee Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p> |
| Kober Lars | <p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Heart Failure Bayer : Heart Failure Boehringer-Ingelheim : Heart Failure Novartis : Heart Failure Novo-Nordisk : Heart Failure</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|-----------------------|---|
| Kober Lars | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Novo-Nordisk : Chronic Heart Failure</p> |
| Koskinas Konstantinos | <p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Cardiology Daiichi Sankyo : Cardiology</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Cardiology</p> |
| | <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> |
| | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> |
| Mcevoy John William | <p>2021</p> <p>Nothing to be declared</p> |
| | <p>2022</p> <p>Nothing to be declared</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry | |
|---------------------|------------------------------------|---|
| Mcevoy John William | 2023 | Nothing to be declared |
| Mihaylova Borislava | 2021 | <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Merck Sharp & Dohme : Anacetrapib National Institute for Health Research (UK), Health Technology Assessment Programme : Cost-effectiveness of statin therapy Barts Charity : Digital pathology National Institute for Health Research : Various clinical studies including economic evaluations</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I am a member of the Editorial Advisory Board of Value in Health (journal). I do not consider this to present any Col.</p> |
| | 2022 | <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Merck Sharp & Dohme : economic analyses alongside a clinical trial, senior health economist Barts Charity : Research project, principal investigator National Institute for Health Research (UK), Health Technology Assessment Programme : Research project, principal investigator Bowel Research UK : research project, principal investigator</p> |
| | 2023 | <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Barts Charity, UK Bowel Research UK Cancer Research UK National Institute for Health and Care Research, UK</p> |
| Mindham Richard | 2021 | <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Imperial College, London : ONCE-OFF Honorarium, 2019, non-recurring, less than GB£900/€1000, passed in full to UK charity, CardiomyopathyUK</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I have a pension and savings held in shares and funds. I do not control which shares are bought and I do not know whether any of them are invested in healthcare organisations as the shares are managed by a fund manager.</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|-----------------|---|
| Mindham Richard | <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. PASSpaces. http://passpaces.co.uk/. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. I support the British charity CardiomyopathyUK, https://www.cardiomyopathy.org.uk/. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, https://pumpingmarvellous.org/. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, https://bureaucracyincts.eu/. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not control the purchase & sale of shares and I do not know whether any shares are in medical companies.</p> |
| | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. NiCE (National Institute for Health & Care Excellence) - UK Government body. Guideline development.. Commences January 2024. : Chronic Heart Failure</p> <p>PASSpaces. http://passpaces.co.uk/. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|-----------------|---|
| Mindham Richard | <p>2023</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. I support the British charity CardiomyopathyUK, https://www.cardiomyopathy.org.uk/. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, https://pumpingmarvellous.org/. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, https://bureaucracyincts.eu/. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not control the purchase & sale of shares and I do not know whether any shares are in medical companies.</p> |
| Neubeck Lis | <p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial fibrillation</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Medical advisor to the Atrial Fibrillation Alliance</p> |
| | <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial Fibrillation (AF),</p> |
| | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Burdett Trust for Nursing Chief Scientists Office</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Daiichi Sankyo : Atrial fibrillation screening, Principal Investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Consultant Editor British Journal of Cardiac Nursing</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry | |
|----------------------|------------------------------------|---|
| Nielsen Jens Cosedis | 2021 | Nothing to be declared |
| | 2022 | <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Have received research funding to my institution for independent research from the Danish Heart Foundation and the Novo Nordisk Foundation.</p> |
| | 2023 | Nothing to be declared |
| Pasquet Agnes A | 2021 | <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : general cardiology Servier : general cardiology Philips : imaging</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. member of the Belgian Society of Cardiology</p> |
| | 2022 | <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Philips : Echocardiography, Interventional Cardiology Daiichi Sankyo : Hypertension Servier : Other</p> |
| | 2023 | <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Philips : echography, contribution and support</p> |
| Prescott Eva | 2021 | Nothing to be declared |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry | |
|-----------------|------------------------------------|--|
| Prescott Eva | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Rakisheva Amina | 2021 | Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Atrial Fibrillatuion Novartis : Heart Failure |
| | 2022 | Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure |
| | 2023 | Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure |
| Rocca Bianca | 2021 | Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer AG : CV prevention in COVID pandemics SOBI : platelet growth factor Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer AG : anticoagulant (rivaroxaban) |
| | 2022 | Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Aboca SRL : Other Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer AG : study on low dose rivaroxaban, Chief investigator |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry | |
|---------------------------|------------------------------------|---|
| Rocca Bianca | 2023 | <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Cancer UK</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Aboca, SRL : Other</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editorial Board of: Assistant Editor Diabetes and Vascular Disease Research Advisory Board: Pharmadvances. Associate Editor: Cardiovascular Drugs and Therapy, Clinical Pharmacology Editorial Board: Bleeding, Thrombosis, and Vascular Biology Associate Editor. Frontiers in Drug Safety and Regulation Section on Cardiovascular Drug Safety Associate Editor for European Cardiology Review Editorial Board European Journal of Preventive Cardiology Editorial Board Journal of Thrombosis and Thrombolysis Editorial Board International Journal of Cardiology</p> |
| Rossello Francisco Javier | 2021 | Nothing to be declared |
| | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Vaartjes Ilonca | 2021 | Nothing to be declared |
| | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Vrints Christiaan Jm | 2021 | Nothing to be declared |
| | 2022 | Nothing to be declared |
| | 2023 | Nothing to be declared |
| Witkowski Adam | 2021 | <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : coronary stents, IVUS, Accurate aortic valves (TAVI), Watchman (LAO) Medtronic : Evolute aortic valves (TAVI) Edwards Lifesciences : Sapien aortic valves (TAVI)</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

| Expert | Type of Relationship with Industry |
|------------------|--|
| Witkowski Adam | <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : Device Therapy Edwards Lifesciences : Device Therapy Medtronic : Device Therapy</p> |
| | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Device Therapy Edwards Lifesciences : Device Therapy Medtronic : Device Therapy</p> |
| Zeppenfeld Katja | <p>2021</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Biosense Webster : Research electrophysiology</p> |
| | <p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Biosense Webster : investigator initiated research, PI</p> |
| | <p>2023</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biosense Webster : Investigator initiated research, ventricular arrhythmias, PI</p> |